Anti-ageing biotech investment surges ahead of scientific understanding

Billions are flowing into anti-ageing biotech, but the science of manipulating ageing remains nascent and risks are poorly understood. The gap between investment and evidence is widening, raising concerns about unproven therapies and potential unintended consequences.